Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Evaluating the implementation and use of the regional cancer plan in Western Sweden through concept mapping.

Smith F, Gunnarsdóttir KÁ, Genell A, McLinden D, Vaughn L, Garelius H, Nilsson-Ehle H, Lönqvist U, Björk-Eriksson T.

Int J Qual Health Care. 2018 Dec 21. doi: 10.1093/intqhc/mzy241. [Epub ahead of print]

PMID:
30576515
2.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

3.

Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients.

Bram Ednersson S, Stenson M, Stern M, Enblad G, Fagman H, Nilsson-Ehle H, Hasselblom S, Andersson PO.

Br J Haematol. 2018 Jun;181(6):770-781. doi: 10.1111/bjh.15259. Epub 2018 May 16.

PMID:
29767447
4.

Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study.

Lewerin C, Ljunggren Ö, Nilsson-Ehle H, Karlsson MK, Herlitz H, Lorentzon M, Ohlsson C, Mellström D.

Bone. 2017 May;98:1-8. doi: 10.1016/j.bone.2017.02.005. Epub 2017 Feb 14.

PMID:
28212898
5.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.

6.

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.

PMID:
27378674
7.

Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.

Stenson M, Pedersen A, Hasselblom S, Nilsson-Ehle H, Karlsson BG, Pinto R, Andersson PO.

Leuk Lymphoma. 2016 Aug;57(8):1814-22. doi: 10.3109/10428194.2016.1140164. Epub 2016 Feb 17.

PMID:
26887805
8.

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

El-Galaly TC, Jakobsen LH, Hutchings M, de Nully Brown P, Nilsson-Ehle H, Székely E, Mylam KJ, Hjalmar V, Johnsen HE, Bøgsted M, Jerkeman M.

J Clin Oncol. 2015 Dec 1;33(34):3993-8. doi: 10.1200/JCO.2015.62.0229. Epub 2015 Oct 5.

PMID:
26438115
9.

SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.

Rüetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, Andersson PO.

Int J Proteomics. 2015;2015:841769. doi: 10.1155/2015/841769. Epub 2015 Apr 28.

10.

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.

Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, Erlanson M, Hagberg H, Rådlund A, Hagberg O, Wahlin BE.

Leukemia. 2015 Mar;29(3):668-76. doi: 10.1038/leu.2014.251. Epub 2014 Aug 25.

PMID:
25151959
11.

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D'Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M.

Blood. 2014 Aug 21;124(8):1288-95. doi: 10.1182/blood-2014-03-559930. Epub 2014 May 23.

12.

Serum estradiol associates with blood hemoglobin in elderly men: the MrOS Sweden study.

Lewerin C, Nilsson-Ehle H, Jacobsson S, Johansson H, Sundh V, Karlsson MK, Lorentzon M, Barrett-Connor E, Vandenput L, Ohlsson C, Mellström D.

J Clin Endocrinol Metab. 2014 Jul;99(7):2549-56. doi: 10.1210/jc.2013-4111. Epub 2014 Apr 14.

PMID:
24731011
13.

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.

14.

Low holotranscobalamin and cobalamins predict incident fractures in elderly men: the MrOS Sweden.

Lewerin C, Nilsson-Ehle H, Jacobsson S, Johansson H, Sundh V, Karlsson MK, Ljunggren Ö, Lorentzon M, Kanis JA, Lerner UH, Cummings SR, Ohlsson C, Mellström D.

Osteoporos Int. 2014 Jan;25(1):131-40. doi: 10.1007/s00198-013-2527-y. Epub 2013 Oct 16.

PMID:
24129588
15.

Holotranscobalamin is not influenced by decreased renal function in elderly men: the MrOS Sweden study.

Lewerin C, Nilsson-Ehle H, Jacobsson S, Karlsson MK, Ohlsson C, Mellström D.

Ann Clin Biochem. 2013 Nov;50(Pt 6):585-94. doi: 10.1177/0004563212474939. Epub 2013 Jul 30.

PMID:
23901143
16.

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Br J Haematol. 2012 Aug;158(3):355-62. doi: 10.1111/j.1365-2141.2012.09174.x. Epub 2012 May 29. Erratum in: Br J Haematol. 2012 Sep;158(6):815-6.

PMID:
22640180
17.

Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.

Hasselblom S, Stenson M, Werlenius O, Sender M, Lewerin C, Hansson U, Nilsson-Ehle H, Andersson PO.

Leuk Lymphoma. 2012 Mar;53(3):394-9. doi: 10.3109/10428194.2011.616612. Epub 2011 Oct 10.

PMID:
21864039
18.

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.

Nilsson-Ehle H, Birgegård G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engström LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellström-Lindberg E.

Eur J Haematol. 2011 Sep;87(3):244-52. doi: 10.1111/j.1600-0609.2011.01654.x. Epub 2011 Jul 26.

PMID:
21623919
19.

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25.

20.

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Hasselblom S, Hansson U, Olsson M, Torén L, Bergström A, Nilsson-Ehle H, Andersson PO.

Br J Haematol. 2010 May;149(4):560-8. doi: 10.1111/j.1365-2141.2010.08123.x. Epub 2010 Mar 1.

PMID:
20201946
21.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570. Epub 2009 Dec 23.

22.

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH.

J Clin Oncol. 2009 Sep 10;27(26):4365-70. doi: 10.1200/JCO.2008.21.3116. Epub 2009 Aug 3.

PMID:
19652064
23.

Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma.

Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO.

Leuk Lymphoma. 2008 Aug;49(8):1501-9. doi: 10.1080/10428190802140055.

PMID:
18766962
24.

Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis.

Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO.

Pathol Int. 2008 Aug;58(8):529-32. doi: 10.1111/j.1440-1827.2008.02268.x.

PMID:
18705775
25.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025. Epub 2008 Jul 14.

26.

Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: Implications for vitamin B12, folic acid and iron status and response to oral vitamin therapy.

Lewerin C, Jacobsson S, Lindstedt G, Nilsson-Ehle H.

Scand J Gastroenterol. 2008;43(9):1050-6. doi: 10.1080/00365520802078341.

PMID:
18609169
27.

The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.

Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO.

Br J Haematol. 2007 May;137(4):364-73.

PMID:
17456059
28.

The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a population-based study.

Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO.

Leuk Lymphoma. 2007 Apr;48(4):736-45.

PMID:
17454632
30.

Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study.

Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson PO; Western Sweden Lymphoma Group.

Leuk Lymphoma. 2006 Dec;47(12):2505-16.

PMID:
17169795
31.

The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL).

Junevik K, Werlenius O, Hasselblom S, Jacobsson S, Nilsson-Ehle H, Andersson PO.

Ann Hematol. 2007 Feb;86(2):89-94. Epub 2006 Oct 17.

PMID:
17043777
33.

Insulin-like growth factor-1 is a predictor of blood haemoglobin concentration in 70-yr-old subjects.

Nilsson-Ehle H, Bengtsson BA, Lindstedt G, Mellström D.

Eur J Haematol. 2005 Feb;74(2):111-6.

PMID:
15654900
34.

False-negative result in the detection of an IgM monoclonal protein by capillary zone electrophoresis.

Zetterberg H, Nilsson-Ehle H.

Clin Chem. 2004 Oct;50(10):1878-80. Epub 2004 Aug 3. No abstract available.

36.
37.

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.

Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P.

Leukemia. 2003 Sep;17(9):1827-33.

PMID:
12970783
38.

Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy.

Andersson PO, Braide I, Nilsson-Ehle H.

Leuk Lymphoma. 2002 Dec;43(12):2351-3.

PMID:
12613523
39.

[B-vitamins and homocysteine--a consensus is necessary!].

Nilsson-Ehle H.

Lakartidningen. 2002 Mar 7;99(10):1106. Swedish. No abstract available.

PMID:
12024795
40.

Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88.

Nilsson-Ehle H, Jagenburg R, Landahl S, Svanborg A.

Eur J Haematol. 2000 Nov;65(5):297-305.

PMID:
11092459
41.

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A.

Blood. 1998 Jul 1;92(1):68-75.

42.

Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy.

Nilsson-Ehle H.

Drugs Aging. 1998 Apr;12(4):277-92. Review.

PMID:
9571392
43.

Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy.

Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B.

Leuk Lymphoma. 1997 Aug;26(5-6):629-32.

PMID:
9389372
44.

Bone marrow progenitor cell growth and karyotype changes in healthy 88-year-old subjects.

Nilsson-Ehle H, Swolin B, Westin J.

Eur J Haematol. 1995 Jul;55(1):14-8.

PMID:
7615045
45.

Anaemia and other haematological abnormalities in patients admitted to long-term care.

Granérus AK, Nilsson-Ehle H, Westin J.

Arch Gerontol Geriatr. 1992 May-Jun;14(3):263-72.

PMID:
15374390
46.

[How to differentiate between health and disease in diagnosing the elderly?].

Jagenburg R, Landahl S, Lindstedt G, Ljunghall S, Nilsson-Ehle H.

Lakartidningen. 1992 Apr 22;89(17):1467-73. Swedish. No abstract available.

PMID:
1573934
47.

[Who is exposed to a life-long unnecessary treatment with vitamin B12?].

Nilsson-Ehle H, Lindstedt S, Jagenburg R.

Lakartidningen. 1992 Apr 22;89(17):1453-4. Swedish. No abstract available.

PMID:
1573929
48.

Serum cobalamins in the elderly: a longitudinal study of a representative population sample from age 70 to 81.

Nilsson-Ehle H, Jagenburg R, Landahl S, Lindstedt S, Svanborg A, Westin J.

Eur J Haematol. 1991 Jul;47(1):10-6.

PMID:
1868911
49.

[Along the Silk Road and in Sweden. Behçet's syndrome--a rare systemic disease affecting mostly younger persons].

Nilsson-Ehle H, Bremell T, Mobacken H, Norrsell K, Rödjer S.

Lakartidningen. 1990 Oct 10;87(41):3311-4. Swedish. No abstract available.

PMID:
2233001
50.

Iron deficiency.

Nilsson-Ehle H.

Ups J Med Sci. 1990;95(3):213-20. No abstract available.

PMID:
2100396

Supplemental Content

Loading ...
Support Center